Company Renalytix Plc Börse Stuttgart
Equities
2O9
GB00BYWL4Y04
Advanced Medical Equipment & Technology
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.117 EUR | -16.43% | -26.70% | -17.16% |
25/06 | Shares in Renalytix plunge on possible ADS suspension on Nasdaq | AN |
25/06 | Renalytix to Appeal Nasdaq Delisting Over Non-compliance | MT |
Business Summary
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Artificial Intelligence-enabled in Vitro Diagnostics
100.0
%
| 2 | 100.0 % | 3 | 100.0 % | +26.61% |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom
100.0
%
| 2 | 100.0 % | 3 | 100.0 % | +26.61% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James McCullough
FOU | Founder | 56 | 15/18/15 |
Howard Doran
PSD | President | 63 | 01/23/01 |
Fergus Fleming
CTO | Chief Tech/Sci/R&D Officer | 57 | 15/18/15 |
Michael Donovan
CTO | Chief Tech/Sci/R&D Officer | 70 | 15/18/15 |
Joseph Hutson
PRN | Corporate Officer/Principal | - | 22/21/22 |
Sales & Marketing | - | 07/21/07 | |
Salim Hamir
SEC | Corporate Secretary | - | - |
Jed Fulk
SAM | Sales & Marketing | 64 | 07/21/07 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Levangie
BRD | Director/Board Member | 73 | 30/21/30 |
Chairman | 72 | 15/18/15 | |
James McCullough
FOU | Founder | 56 | 15/18/15 |
Fergus Fleming
CTO | Chief Tech/Sci/R&D Officer | 57 | 15/18/15 |
Erik Lium
BRD | Director/Board Member | 56 | 01/18/01 |
Catherine Coste
BRD | Director/Board Member | 58 | 30/23/30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 154,368,191 | 94,984,051 ( 61.53 %) | 0 | 61.53 % |
Company contact information
Sector
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-35.26% | 14.88B | |
-54.48% | 2.26B | |
+19.59% | 1.89B | |
-11.85% | 1.52B | |
+19.52% | 1.19B | |
-29.99% | 871M | |
+2.28% | 781M | |
-34.22% | 750M | |
-29.32% | 591M |
- Stock Market
- Equities
- RENX Stock
- 2O9 Stock
- Company Renalytix Plc